Full View

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

B Rocca, A Tosetto, S Betti, D Soldati… - Blood, The Journal …, 2020 - ashpublications.org
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and
enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic …
被引用次数：96 相关文章

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

B Rocca, A Tosetto, S Betti, D Soldati, G Petrucci… - 2020 - pubmed.ncbi.nlm.nih.gov
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and
enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic …

A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

B Rocca, A Tosetto, S Betti, D Soldati, G Petrucci… - BLOOD, 2020 - publicatt.unicatt.it
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and
enhanced thrombotic risk. Once-daily (od), low-dose aspirin is the recommended …

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

B Rocca, A Tosetto, S Betti, D Soldati, G Petrucci… - BLOOD, 2020 - air.unimi.it
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and
enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic …

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

B Rocca, A Tosetto, S Betti, D Soldati, GPE Rossi… - BLOOD, 2020 - ricerca.unich.it
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and
enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic …

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.

B Rocca, A Tosetto, S Betti, D Soldati, G Petrucci… - Blood, 2020 - europepmc.org
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and
enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic …
[HTML] sciencedirect.com

[HTML][HTML] A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

B Rocca, A Tosetto, S Betti, D Soldati, G Petrucci… - Blood, 2020 - Elsevier
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and
enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic …

A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

B Rocca, A Tosetto, S Betti, D Soldati, G Petrucci… - BLOOD, 2020 - flore.unifi.it
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and
enhanced thrombotic risk. Once-daily (od), low-dose aspirin is the recommended …

A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

V De Stefano, C Patrono, F Rodeghiero, AM Vannucchi… - BLOOD, 2020 - research.unipd.it
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and
enhanced thrombotic risk. Once-daily (od), low-dose aspirin is the recommended …

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

B Rocca, A Tosetto, S Betti, D Soldati, G Petrucci… - Blood, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Essential thrombocythemia (ET) is
characterized by abnormal megakaryopoiesis and enhanced thrombotic risk. Once-daily low …